ORIC · Insider Trading
Oric Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by ORIC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Dominic Piscitelli | Chief Financial Officer | MIXED | — | −$128.35K |
| 2026-10-02 | Richard A. Heyman | Director | MIXED | −3,200 | −$80.92K |
| 2026-09-29 | Dominic Piscitelli | Chief Financial Officer | MIXED | — | −$122.83K |
| 2026-09-25 | Dominic Piscitelli | Chief Financial Officer | MIXED | — | −$5.49K |
| 2026-08-28 | Dominic Piscitelli | Chief Financial Officer | MIXED | — | −$677.09K |
| 2026-07-28 | Richard A. Heyman | Director | MIXED | −9,600 | −$151.86K |
| 2026-07-08 | Richard A. Heyman | Director | Sell | −300 | −$3.60K |
| 2026-02-26 | Dominic Piscitelli | Chief Financial Officer | MIXED | — | −$475.97K |
| 2026-01-20 | Richard A. Heyman | Director | Sell | −6,700 | −$80.43K |
| 2026-01-06 | Jacob Chacko | PRESIDENT AND CEO | A | +787,500 deriv. | — |
| 2026-01-06 | Steven L. Hoerter | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Richard A. Heyman | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Lori Anne Kunkel | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Pratik S Multani | Chief Medical Officer | A | +249,500 deriv. | — |
| 2026-01-06 | Dominic Piscitelli | Chief Financial Officer | A | +241,000 deriv. | — |
| 2026-01-06 | Angie You | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Mardi Dier | Director | A | +40,000 deriv. | — |
| 2025-12-17 | Dominic Piscitelli | Chief Financial Officer | MIXED | +18,613 | −$97.13K |
| 2025-12-17 | Jacob Chacko | PRESIDENT AND CEO | MIXED | +50,292 | −$302.37K |
| 2025-12-17 | Pratik S Multani | Chief Medical Officer | MIXED | +18,613 | −$97.13K |
| 2025-12-09 | Lori Anne Kunkel | Director | M | +10,000 | +$79.00K |
| 2025-12-05 | Lori Anne Kunkel | Director | M | +5,534 | +$20.75K |
| 2025-10-08 | Jacob Chacko | PRESIDENT AND CEO | Sell | −37,461 | −$461.52K |
| 2025-10-08 | Dominic Piscitelli | Chief Financial Officer | MIXED | — | −$111.76K |
| 2025-10-03 | Richard A. Heyman | Director | M | +32,800 | +$55.59K |
| 2025-10-02 | Jacob Chacko | PRESIDENT AND CEO | Sell | −87,539 | −$1.05M |
| 2025-09-24 | Jacob Chacko | PRESIDENT AND CEO | Sell | −125,000 | −$1.35M |
| 2025-07-02 | Dominic Piscitelli | Chief Financial Officer | Sell | −20,000 | −$200.97K |
| 2025-06-24 | Dominic Piscitelli | Chief Financial Officer | Sell | −33,500 | −$351.38K |
| 2025-06-23 | Angie You | Director | Buy | +28,000 | +$262.90K |
| 2025-06-13 | Dominic Piscitelli | Chief Financial Officer | Sell | −300 | −$3.00K |
| 2025-06-11 | Dominic Piscitelli | Chief Financial Officer | Sell | −3,300 | −$33.02K |
| 2025-06-09 | Dominic Piscitelli | Chief Financial Officer | Sell | −2,900 | −$29.02K |
| 2025-03-04 | Lori Anne Kunkel | Director | M | +48,166 | +$233.51K |
| 2025-01-06 | Lori Anne Kunkel | Director | A | +35,000 deriv. | — |
| 2025-01-06 | Angie You | Director | A | +35,000 deriv. | — |
| 2025-01-06 | Steven L. Hoerter | Director | A | +35,000 deriv. | — |
| 2025-01-06 | Mardi Dier | Director | A | +35,000 deriv. | — |
| 2025-01-06 | Richard A. Heyman | Director | A | +35,000 deriv. | — |
| 2025-01-03 | Jacob Chacko | PRESIDENT AND CEO | A | +700,000 deriv. | — |
| 2025-01-03 | Pratik S Multani | Chief Medical Officer | A | +236,500 deriv. | — |
| 2025-01-03 | Dominic Piscitelli | Chief Financial Officer | A | +236,500 deriv. | — |
| 2024-12-17 | Dominic Piscitelli | Chief Financial Officer | MIXED | +15,191 | −$73.30K |
| 2024-12-17 | Pratik S Multani | Chief Medical Officer | MIXED | +15,192 | −$73.29K |
| 2024-12-17 | Jacob Chacko | PRESIDENT AND CEO | MIXED | +42,340 | −$204.21K |
| 2024-06-14 | Richard A. Heyman | Director | A | +25,600 deriv. | — |
| 2024-06-14 | Angie You | Director | A | +25,600 deriv. | — |
| 2024-06-14 | Lori Anne Kunkel | Director | A | +25,600 deriv. | — |
| 2024-06-14 | Mardi Dier | Director | A | +25,600 deriv. | — |
| 2024-06-14 | Steven L. Hoerter | Director | A | +25,600 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jacob Chacko | PRESIDENT AND CEO | 581,711 | $5.21M |
| Richard A. Heyman | Director | 241,772 | $2.17M |
| Lori Anne Kunkel | Director | 84,200 | $754.01K |
| Dominic Piscitelli | Chief Financial Officer | 69,828 | $625.31K |
| Pratik S Multani | Chief Medical Officer | 68,149 | $610.27K |
| Angie You | Director | 26,597 | $238.18K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ORIC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.